Lindsay Peterson, MD
Medical Oncology · Saint Louis, MONPI 1194900134
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.3%), grants and food and beverage — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 84.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $897 and has fallen 84.9% since, to $135 in 2025. That places this record below the midpoint for medical oncology clinicians in MO, where the typical reported total is $3,595.
Across 8 payments — averaging $133.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$897
- Tempus AI, Inc$96
- Gilead$39
- Merck$33
Across 21 payments — averaging $10,259 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$165K
- Tolmar, Inc.$50K
What the payments were for
- Consulting fees$52549%
- Grants$35033%
- Food & beverage$19118%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $897 |
| Tempus AI, Inc | 1 | $96 |
| Gilead | 2 | $39 |
| Merck | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Truqap$525
How this compares
$1,066 in reported general payments places this provider in the 35th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 24 | $397,158 |
| IbrancePalbociclib | 23 | $365,522 |
| VerzenioAbemaciclib | 14 | $190,119 |
| EliquisApixaban | 29 | $21,038 |
| Anastrozole | 236 | $2,679 |
| Tamoxifen Citrate | 55 | $1,170 |
| Letrozole | 79 | $923 |
| Prochlorperazine Maleate | 22 | $660 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $479 |
| Dexamethasone | 29 | $342 |
| Duloxetine Hcl | 14 | $190 |
| Gabapentin | 31 | $174 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Saint Louis
- Brad KahlSaint Louis$336K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Milan ChhedaSaint Louis$105K
- Maurice WillisSaint Louis$101K
- Moh'd KhushmanSaint Louis$84K
- Camille AbboudSaint Louis$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.